NPPA Caps Retail Prices Of 13 Formulations
Mumbai, 12 Feb 2021:
The National Pharmaceutical Pricing Authority (NPPA) has fixed retail price of 13 formulations under Drugs Prices Control Order (DPCO) 2013 based on the decision of 83rd Authority Meeting dated January 27, 2021.
The formulations include rosuvastatin + aspirin capsule, telmisartan, cilnidipine and chlorthalidone tablet, rosuvastatin + clopidogrel tablet, rosuvastatin + clopidogrel tablet, mefanamic acid + paracetamol suspension (Pyremol-MF) and vildagliptin + metformin hydrochloride (SR) tablet.
The manufacturer of these formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified. The manufacturer may add goods and services tax only if they have paid actually or it is payable to the government on the retail price as prescribed by NPPA.
The retail price for a pack of these formulations shall be arrived at by the concerned manufacturer in accordance with the retail price specified as per provisions contained in paragraph 11 of the DPCO, 2013.
The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller (SDC) and dealers.
As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
The retail price fixed is applicable only to the individual manufacturer/marketer as specified i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO 2013.
In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.Pharmabiz